Meir Medical Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gottfried, Maya
SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Recruiting
1/2
120
RoW
Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
03/25
03/25
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Levy, Yair
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
3
300
Europe, Canada, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
02/27
02/27
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated
2
19
Europe, US, RoW
Daxdilimab, Placebo (Normal Saline)
Amgen, Horizon Therapeutics Ireland DAC
Lupus Nephritis
01/24
01/24
NCT03473912: Meir Medical Center Rheumatologic Biobank

Recruiting
N/A
500
RoW
Meir Medical Center
Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, IgG4-related Disease, Sjogren's Syndrome
11/37
11/37
levy, yaei
No trials found

Download Options